PPARβ/δ agonists, such as GW501516, were reported to significantly enhance the growth of various hepatoma cells, whereas inhibition of PPARβ/δ expression by siRNAs had the opposite effect [113]. This evidence concerns the gene PPARD and hepatocellular carcinoma.